Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday
Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics
Trending Stocks Today | American Tower Corp Dips 3.58% Post-Market
12 Health Care Stocks Moving In Thursday's After-Market Session
Sangamo Therapeutics Stock Surges After The Bell: What's Going On?
Sangamo Therapeutics Enters Capsid License Agreement With Lilly
Express News | Sangamo Therapeutics Inc: Sangamo to Receive an $18 Mln Upfront License Fee
Express News | Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 28% Price Drop
Wells Fargo Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Maintains Target Price $2
Jefferies Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Cuts Target Price to $2
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Sangamo Therapeutics Analyst Ratings
Barclays Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $9
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday
Sangamo Therapeutics Advances Neurology Pipeline Amid Financial Restructuring
Earnings Call Summary | Sangamo Therapeutics(SGMO.US) Q4 2024 Earnings Conference